Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $61.49 (market cap $78.85B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.24% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MDLZ | VRTX | |
|---|---|---|
Market Cap | $78.85B | $134.25B |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $529.65 |
52-Week Low | $51.51 | $376.62 |
Enterprise Value | $99.19B | $128.37B |
Dividend Yield | 3.24% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
